SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes(California Institute of Technology), Claudia A. Jette(California Institute of Technology), Morgan E. Abernathy(California Institute of Technology), Kim-Marie A. Dam(California Institute of Technology), Shannon R. Esswein(California Institute of Technology), Harry B. Gristick(California Institute of Technology), Andrey Malyutin(California Institute of Technology), Naima G. Sharaf(California Institute of Technology), Kathryn E. Huey‐Tubman(California Institute of Technology), Yu E. Lee(California Institute of Technology), Davide F. Robbiani(Università della Svizzera italiana), Michel C. Nussenzweig(Howard Hughes Medical Institute), Anthony P. West(California Institute of Technology), Pamela J. Björkman(California Institute of Technology)
Nature
October 12, 2020
Cited by 1,862Open Access
Full Text

Abstract


Related Papers

Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al.|Acta Crystallographica Section D Biological Crystallography|2010|29.4k
Overview of the<i>CCP</i>4 suite and current developments
Martyn Winn, Charles Ballard, Kevin Cowtan et al.|Acta Crystallographica Section D Biological Crystallography|2011|12.5k